Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human molecular …, 2016 - academic.oup.com
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …
被引用次数：20 相关文章
[PDF] researchgate.net

[PDF][PDF] Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan, M Deng… - researchgate.net
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …

Metformin pharmacogenomics: A genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human molecular …, 2016 - researchwithrutgers.com
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …

Metformin pharmacogenomics: A genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human …, 2016 - mayoclinic.elsevierpure.com
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …

Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human Molecular …, 2016 - search.ebscohost.com
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …

Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human Molecular …, 2016 - europepmc.org
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …

Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human molecular …, 2016 - pubmed.ncbi.nlm.nih.gov
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …
[HTML] nih.gov

[HTML][HTML] Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human Molecular …, 2016 - ncbi.nlm.nih.gov
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …

Metformin pharmacogenomics: a genome-wide association study to identify genetic and epigenetic biomarkers involved in metformin anticancer response using …

N Niu, T Liu, J Cairns, RC Ly, X Tan… - Human Molecular …, 2016 - europepmc.org
Metformin is currently considered as a promising anticancer agent in addition to its anti-
diabetic effect. To better individualize metformin therapy and explore novel molecular …